Literature DB >> 25405669

Advances in acute asthma.

Gustavo J Rodrigo1.   

Abstract

PURPOSE OF REVIEW: The purpose of this study is to highlight some of the recent findings related with the management of acute exacerbations in the context of the emergency department setting. RECENT
FINDINGS: β₂-agonist heliox-driven nebulization significantly increased by 17% [95% confidence interval (CI) 5.2-29.4] peak expiratory flow, and decreased the rate of hospital admissions (risk ratio 0.77, 95% CI 0.62-0.98), compared with oxygen-driven nebulization. Other findings indicate that there is no robust evidence to support the use of intravenous or nebulized magnesium sulphate in adults with severe acute asthma, and that levalbuterol was not superior to albuterol regarding efficacy and safety in individuals with acute asthma. Finally, hyperlactatemia developed during the first hours of acute asthma treatment has a high prevalence, is related with the use of β₂-agonists and had no clinical consequences.
SUMMARY: After a comprehensive review of the best quality pieces of literature published in the last year, it is possible to conclude that the goals of acute asthma management remain almost unchanged.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25405669     DOI: 10.1097/MCP.0000000000000123

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  2 in total

Review 1.  Chinese expert consensus-based guideline on assessment and management of asthma exacerbation.

Authors:  Jiangtao Lin; Bin Xing; Ping Chen; Mao Huang; Xin Zhou; Changgui Wu; Dong Yang; Kaisheng Yin; Shaoxi Cai; Xiaoming Cheng; Chuangli Hao; Changzheng Wang; Chuntao Liu
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

2.  Tomatidine Attenuates Airway Hyperresponsiveness and Inflammation by Suppressing Th2 Cytokines in a Mouse Model of Asthma.

Authors:  Chieh-Ying Kuo; Wen-Chung Huang; Chian-Jiun Liou; Li-Chen Chen; Jiann-Jong Shen; Ming-Ling Kuo
Journal:  Mediators Inflamm       Date:  2017-11-21       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.